» Articles » PMID: 39889806

Bacteria-tumor Symbiosis Destructible Novel Nanocatalysis Drug Delivery Systems for Effective Tumor Therapy

Overview
Date 2025 Jan 31
PMID 39889806
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a significant threat to human health. The dynamic equilibrium between probiotics and pathogenic bacteria within the gut microbiota is crucial in mitigating the risk of CRC. An overgrowth of harmful microorganisms in the gastrointestinal tract can result in an excessive accumulation of bacterial toxins and carcinogenic metabolites, thereby disrupting the delicate balance of the microbiota. This disruption may lead to alterations in microbial composition, impairment of mucosal barrier function, potential promotion of abnormal cell proliferation, and ultimately contribute to the progression of CRC. Recently, research has indicated that intestinal presence of (Fn) significantly influences the onset, progression, and metastasis of CRC. Consequently, disrupting the interaction between CRC cells and Fn presents a promising strategy against CRC. Nanomaterials have been extensively utilized in cancer therapy and bacterial infection control, demonstrating substantial potential in treating bacteria-associated tumors. This review begins by elucidating the mechanisms of gut microbiota and the occurrence and progression of CRC, with a particular emphasis on clarifying the intricate relationship between Fn and CRC. Subsequently, we highlight strategies that utilize nanomaterials to disrupt the association between Fn and CRC. Overall, this review offers valuable insight and guidance for leveraging nanomaterials in CRC therapy.

References
1.
Wang X, Chen Q, Zhu Y, Wang K, Chang Y, Wu X . Destroying pathogen-tumor symbionts synergizing with catalytic therapy of colorectal cancer by biomimetic protein-supported single-atom nanozyme. Signal Transduct Target Ther. 2023; 8(1):277. PMC: 10359331. DOI: 10.1038/s41392-023-01491-8. View

2.
Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y . Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. Gastroenterology. 2016; 152(4):851-866.e24. PMC: 5555435. DOI: 10.1053/j.gastro.2016.11.018. View

3.
Su M, Wen X, Yu Y, Li N, Li X, Qu X . Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against -associated colorectal tumor. J Mater Chem B. 2024; 12(16):3947-3958. DOI: 10.1039/d4tb00103f. View

4.
Liu M, An R, Wu Z, Dai L, Zeng Q, Chen W . The Trajectory of Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiotherapy and its Influencing Factors. Ear Nose Throat J. 2024; :1455613241228211. DOI: 10.1177/01455613241228211. View

5.
Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N . Tumor Cell-Targeting and Tumor Microenvironment-Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic/Photothermal/Chemodynamic Treatment of Cervical Cancer. Int J Nanomedicine. 2024; 19:5837-5858. PMC: 11182360. DOI: 10.2147/IJN.S466042. View